tiprankstipranks
Syros Pharmaceuticals Reports Q3 2024 Financial Results
Company Announcements

Syros Pharmaceuticals Reports Q3 2024 Financial Results

Syros Pharmaceuticals ( (SYRS) ) has released its Q3 earnings. Here is a breakdown of the information Syros Pharmaceuticals presented to its investors.

Don't Miss our Black Friday Offers:

Syros Pharmaceuticals, Inc., a biopharmaceutical company headquartered in Cambridge, Massachusetts, focuses on developing treatments for hematologic malignancies. In their latest earnings report for Q3 2024, Syros Pharmaceuticals reported a net loss of $6.4 million, a significant improvement from the $40.1 million loss in the same quarter last year. Despite the decrease in operating expenses, the company saw no revenue due to the termination of a collaboration agreement. Key financial metrics included a reduction in cash and cash equivalents from $139.5 million at year-end 2023 to $58.3 million as of September 2024. The company’s restructuring efforts, including a 35% workforce reduction, were implemented to prioritize the development of tamibarotene, a treatment for myelodysplastic syndrome and acute myeloid leukemia. Looking ahead, Syros Pharmaceuticals plans to focus on advancing tamibarotene and exploring additional financing options to support its operations.

Related Articles
TipRanks Auto-Generated NewsdeskSyros Pharmaceuticals Faces Financial Struggles Amid Key Challenges
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlySyros Pharmaceuticals downgraded to Hold from Buy at TD Cowen
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App